Observational studyArthritis research & therapy2026
Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database.
Observational study in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to explore the risk factors of serious infections (SI) in patients with large-vessel vasculitis (LVV) in Japan.
methodsThis observational nested case-control study used an administrative claims database (April 2008 to July 2023) provided by Medical Data Vision Co., Ltd. Patients with Takayasu arteritis (TAK) and giant cell arteritis (GCA) were identified based on age and prescription of oral glucocorticoids (GC) or immunosuppressants following a definite diagnosis code. An SI was defined as an infection-related hospitalization. We identified a maximum of five controls for each case that were matched for sex, age, days of follow-up, and calendar year. The adjusted odds ratios (aORs) and 95% confidence intervals for the association between SI and risk factors were estimated using conditional logistic regression.
resultsAmong 1,856 patients with TAK and 2,149 patients with GCA, 151 (8.1%) and 202 SI cases (9.4%) were identified from the TAK and GCA cohorts, respectively. The respiratory tract was the most frequent site of infection. Injectable GCs were significantly associated with SI. No significant increase in the aORs of tocilizumab was observed in either cohort. Significant comorbid risk factors included diabetes mellitus and malignant tumor in both cohorts; respiratory disease and renal dysfunction in the TAK cohort; and cerebral or cardiovascular disease in the GCA cohort.
conclusionConsidering these risk factors, close monitoring, prevention, and management of SI are clinically important to prevent the occurrence of SI in patients with LVV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.